NASDAQ:CLSN - Celsion Stock Price, Price Target & More

$2.32 +0.04 (+1.75 %)
(As of 04/20/2018 11:00 AM ET)
Previous Close$2.28
Today's Range$2.28 - $2.35
52-Week Range$1.24 - $6.06
Volume36,745 shs
Average Volume290,231 shs
Market Capitalization$39.92 million
P/E Ratio-0.97
Dividend YieldN/A
Beta1.66

About Celsion (NASDAQ:CLSN)

Celsion logoCelsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100

Debt

Debt-to-Equity RatioN/A
Current Ratio3.93%
Quick Ratio3.93%

Price-To-Earnings

Trailing P/E Ratio-0.97
Forward P/E Ratio-1.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales82.31
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book1.40

Profitability

EPS (Most Recent Fiscal Year)($2.39)
Net Income$-20,400,000.00
Net Margins-4,030.49%
Return on Equity-163.12%
Return on Assets-54.46%

Miscellaneous

Employees21
Outstanding Shares17,740,000

How to Become a New Pot Stock Millionaire

Celsion (NASDAQ:CLSN) Frequently Asked Questions

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion's stock split? How did Celsion's stock split work?

Shares of Celsion reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings results on Thursday, May, 18th. The biotechnology company reported ($1.64) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.30) by $0.34. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 4,030.49% and a negative return on equity of 163.12%. View Celsion's Earnings History.

When is Celsion's next earnings date?

Celsion is scheduled to release their next quarterly earnings announcement on Friday, May, 11th 2018. View Earnings Estimates for Celsion.

What price target have analysts set for CLSN?

2 brokerages have issued 1-year price objectives for Celsion's stock. Their forecasts range from $7.00 to $9.00. On average, they anticipate Celsion's share price to reach $8.00 in the next twelve months. View Analyst Ratings for Celsion.

What are Wall Street analysts saying about Celsion stock?

Here are some recent quotes from research analysts about Celsion stock:
  • 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (4/3/2018)
  • 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)

Who are some of Celsion's key competitors?

Who are Celsion's key executives?

Celsion's management team includes the folowing people:
  • Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 67)
  • Mr. Jeffrey W. Church, CFO, Sr. VP of Corp. Strategy & IR and Corp. Sec. (Age 61)
  • Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 58)
  • Dr. Nicholas Borys, Sr. VP & Chief Medical Officer (Age 59)
  • Mr. Timothy J. Tumminello CPA, Chief Accounting Officer and Controller (Age 60)

Has Celsion been receiving favorable news coverage?

Media stories about CLSN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Celsion earned a news impact score of 0.16 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 44.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $2.32.

How big of a company is Celsion?

Celsion has a market capitalization of $39.92 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-20,400,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Celsion employs 21 workers across the globe.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]


MarketBeat Community Rating for Celsion (CLSN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celsion (NASDAQ:CLSN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Celsion in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 244.83%. The high price target for CLSN is $9.00 and the low price target for CLSN is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$14.50$14.50$16.3333
Price Target Upside: 244.83% upside577.57% upside577.57% upside169.53% upside

Celsion (NASDAQ:CLSN) Consensus Price Target History

Price Target History for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ:CLSN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017OppenheimerInitiated CoverageOutperform$9.00N/AView Rating Details
10/4/2017Maxim GroupUpgradeHold -> Buy$7.00HighView Rating Details
4/10/2017Rodman & RenshawReiterated RatingBuy$21.00HighView Rating Details
4/10/2017HC WainwrightReiterated RatingBuy$21.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Celsion (NASDAQ:CLSN) Earnings History and Estimates Chart

Earnings by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ:CLSN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.37)($0.37)($0.37)
Q2 20181($0.39)($0.39)($0.39)
Q3 20181($0.38)($0.38)($0.38)
Q4 20181($0.30)($0.30)($0.30)

Celsion (NASDAQ CLSN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2018        
11/14/2017Q3 2017($0.56)($0.39)$0.13 million$0.13 millionViewN/AView Earnings Details
8/14/2017Q2 2017($1.10)($0.79)$0.13 million$0.13 millionViewN/AView Earnings Details
5/18/2017Q1 2017($1.3020)($1.6380)$0.13 million$0.13 millionViewN/AView Earnings Details
3/16/2017Q4 2016($2.24)($1.96)$0.13 million$0.13 millionViewN/AView Earnings Details
11/10/2016Q3 2016($2.66)($3.22)$0.13 million$0.13 millionViewN/AView Earnings Details
8/15/2016Q2($2.94)($2.66)$0.13 million$0.13 millionViewListenView Earnings Details
5/16/2016Q116($2.94)($3.36)$0.13 million$0.13 millionViewListenView Earnings Details
3/30/2016Q415($3.36)($3.36)$0.16 million$0.13 millionViewListenView Earnings Details
11/5/2015Q315($3.64)($2.80)$0.14 million$0.13 millionViewN/AView Earnings Details
8/10/2015Q215($4.34)($3.78)$0.16 million$0.13 millionViewListenView Earnings Details
5/12/2015Q1($4.62)($4.76)$0.13 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q4 2014($5.04)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
11/11/2014Q3 2014($4.20)($4.90)$0.16 million$0.13 millionViewN/AView Earnings Details
8/7/2014Q214($3.92)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
5/8/2014Q1 2014($2.80)($4.62)$0.13 million$0.13 millionViewN/AView Earnings Details
3/13/2014($3.92)($2.66)$0.13 million$0.13 millionViewN/AView Earnings Details
11/12/2013Q3($3.15)($4.20)$0.1250 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.98)$0.14$0.1250 millionViewN/AView Earnings Details
5/9/2013Q1 2013($2.24)($1.68)$0.38 million$0.13 millionViewN/AView Earnings Details
3/18/2013Q4 2012($10.72)($13.24)ViewN/AView Earnings Details
11/12/2012Q312($2.38)($2.52)ViewN/AView Earnings Details
8/14/2012Q2 2012($11.98)($11.60)ViewN/AView Earnings Details
5/15/2012Q1 2012($13.24)($11.72)ViewN/AView Earnings Details
3/15/2012Q4 2011($13.87)($11.35)ViewN/AView Earnings Details
11/10/2011Q3 2011($16.39)($16.01)ViewN/AView Earnings Details
8/9/2011Q2 2011($24.46)ViewN/AView Earnings Details
5/12/2011Q1 2011($18.41)ViewN/AView Earnings Details
3/25/2011Q4 2010($26.47)ViewN/AView Earnings Details
11/15/2010Q3 2010($23.32)($24.08)ViewN/AView Earnings Details
8/3/2010Q2 2010($23.95)($23.01)ViewN/AView Earnings Details
5/4/2010Q1 2010($20.17)($23.64)ViewN/AView Earnings Details
2/17/2010Q4 2009($22.69)($11.85)ViewN/AView Earnings Details
11/10/2009Q3 2009($29.37)ViewN/AView Earnings Details
8/5/2009Q2 2009($28.36)ViewN/AView Earnings Details
5/12/2009Q1 2009($22.38)ViewN/AView Earnings Details
3/3/2009Q4 2008($5.80)ViewN/AView Earnings Details
11/13/2008Q3 2008($26.98)ViewN/AView Earnings Details
8/18/2008Q2 2008($15.06)ViewN/AView Earnings Details
5/8/2008Q1 2008($25.34)ViewN/AView Earnings Details
2/21/2008Q4 2007($15.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Celsion (NASDAQ:CLSN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Celsion (NASDAQ CLSN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 3.83%
Insider Trading History for Celsion (NASDAQ:CLSN)
Institutional Ownership by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ CLSN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/9/2018Michael H TardugnoCEOBuy2,500$2.30$5,750.0020,200View SEC Filing  
3/5/2018Michael H TardugnoCEOBuy7,500$2.38$17,850.0017,700View SEC Filing  
2/22/2018Alberto R Martinez JrDirectorBuy7,143$2.17$15,500.3120,000View SEC Filing  
2/20/2018Frederick J FritzDirectorBuy6,000$2.17$13,020.0012,841View SEC Filing  
7/7/2017Frederick J FritzDirectorBuy13,000$1.89$24,570.009,841View SEC Filing  
2/21/2017Alberto R Martinez JrDirectorBuy35,000$0.23$8,050.00180,081View SEC Filing  
2/15/2017Alberto R Martinez JrDirectorBuy45,000$0.22$9,900.00145,081View SEC Filing  
11/14/2016Alberto R Martinez JrDirectorBuy10,000$0.86$8,600.00100,081View SEC Filing  
11/11/2016Alberto R Martinez JrDirectorBuy10,000$0.91$9,100.0090,081View SEC Filing  
10/7/2016Michael H TardugnoChairmanBuy10,000$1.14$11,400.00143,021View SEC Filing  
8/16/2016Alberto R Martinez JrDirectorBuy5,000$1.25$6,250.0080,081View SEC Filing  
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.0075,081View SEC Filing  
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00128,021View SEC Filing  
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00120,521View SEC Filing  
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00117,521View SEC Filing  
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.0070,081View SEC Filing  
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00115,521View SEC Filing  
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00111,021View SEC Filing  
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.482,421,867View SEC Filing  
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.002,442,423View SEC Filing  
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.002,462,423View SEC Filing  
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.002,472,423View SEC Filing  
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.0021,331View SEC Filing  
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.0057,521View SEC Filing  
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.0053,521View SEC Filing  
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.0014,331View SEC Filing  
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.0051,000View SEC Filing  
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00228,285View SEC Filing  
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celsion (NASDAQ CLSN) News Headlines

Source:
DateHeadline
International Liver Congress™ 2018 Symposium Highlights Celsions ThermoDox® in Treatment of Primary Liver CancerInternational Liver Congress™ 2018 Symposium Highlights Celsion's ThermoDox® in Treatment of Primary Liver Cancer
globenewswire.com - April 12 at 10:53 AM
International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver CancerInternational Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
finance.yahoo.com - April 12 at 10:53 AM
Form 4 Celsion CORP For: Apr 09 Filed by: Tardugno Michael HForm 4 Celsion CORP For: Apr 09 Filed by: Tardugno Michael H
www.streetinsider.com - April 9 at 4:07 PM
Celsion (CLSN) Says DMC Completes Planned Safety and Data Review of its Phase III OPTIMA Study of ThermoDox in ...Celsion (CLSN) Says DMC Completes Planned Safety and Data Review of its Phase III OPTIMA Study of ThermoDox in ...
www.streetinsider.com - April 9 at 4:07 PM
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsions Phase III OPTIMA Study of ...Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion's Phase III OPTIMA Study of ...
globenewswire.com - April 9 at 10:23 AM
Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver CancerData Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
finance.yahoo.com - April 9 at 10:23 AM
Celsion (CLSN) Cut to "Sell" at Zacks Investment ResearchCelsion (CLSN) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:54 PM
Celsion (CLSN) Downgraded to Sell at ValuEngineCelsion (CLSN) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 28 at 10:22 PM
Edited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMTEdited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMT
finance.yahoo.com - March 28 at 10:01 AM
Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial ResultsCelsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 27 at 10:11 AM
Celsion Co. (CLSN) Receives Consensus Recommendation of "Buy" from AnalystsCelsion Co. (CLSN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 26 at 8:26 AM
Celsion (CLSN) Downgraded by ValuEngine to Strong SellCelsion (CLSN) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 25 at 7:32 PM
Celsion (CLSN) Lifted to Hold at ValuEngineCelsion (CLSN) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 23 at 11:20 PM
Celsion (CLSN) Set to Announce Quarterly Earnings on TuesdayCelsion (CLSN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 23 at 8:20 PM
$130,000.00 in Sales Expected for Celsion Co. (CLSN) This Quarter$130,000.00 in Sales Expected for Celsion Co. (CLSN) This Quarter
www.americanbankingnews.com - March 21 at 8:49 AM
Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
finance.yahoo.com - March 20 at 9:51 AM
Celsion (CLSN) Rating Increased to Sell at ValuEngineCelsion (CLSN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 19 at 11:48 PM
Critical Comparison: Celsion (CLSN) versus Edge Therapeutics (EDGE)Critical Comparison: Celsion (CLSN) versus Edge Therapeutics (EDGE)
www.americanbankingnews.com - March 17 at 3:06 AM
Celsion (CLSN) Downgraded by ValuEngineCelsion (CLSN) Downgraded by ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
Celsion Corporation to Present at Upcoming Investor ConferencesCelsion Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - March 12 at 4:02 PM
Celsion Co. (CLSN) CEO Michael H. Tardugno Acquires 7,500 SharesCelsion Co. (CLSN) CEO Michael H. Tardugno Acquires 7,500 Shares
www.americanbankingnews.com - March 5 at 12:38 PM
Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor EventCelsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event
finance.yahoo.com - March 5 at 10:59 AM
Zacks: Analysts Anticipate Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00Zacks: Analysts Anticipate Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - March 4 at 5:46 AM
-$0.31 EPS Expected for Celsion Co. (CLSN) This Quarter-$0.31 EPS Expected for Celsion Co. (CLSN) This Quarter
www.americanbankingnews.com - March 2 at 12:08 PM
Celsion Co. (CLSN) Given Consensus Rating of "Buy" by AnalystsCelsion Co. (CLSN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 1 at 12:10 PM
Celsion Co. (CLSN) Director Purchases $15,500.31 in StockCelsion Co. (CLSN) Director Purchases $15,500.31 in Stock
www.americanbankingnews.com - February 22 at 3:26 PM
Frederick J. Fritz Acquires 6,000 Shares of Celsion Co. (CLSN) StockFrederick J. Fritz Acquires 6,000 Shares of Celsion Co. (CLSN) Stock
www.americanbankingnews.com - February 21 at 12:31 PM
 Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00 Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - February 15 at 3:36 AM
Zacks: Brokerages Expect Celsion Co. (CLSN) to Announce -$0.31 EPSZacks: Brokerages Expect Celsion Co. (CLSN) to Announce -$0.31 EPS
www.americanbankingnews.com - February 13 at 3:12 PM
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Associations 12th Annual ... - GlobeNewswire (press release)Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association's 12th Annual ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:01 AM
Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific MeetingCelsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting
finance.yahoo.com - February 12 at 3:21 PM
Celsion Co. (CLSN) Receives Average Rating of "Buy" from BrokeragesCelsion Co. (CLSN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 4 at 8:02 AM
Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - January 29 at 3:46 AM
Celsion Corporation Provides Corporate Update and 2018 OutlookCelsion Corporation Provides Corporate Update and 2018 Outlook
finance.yahoo.com - January 18 at 10:38 AM
Celsion (CLSN) Downgraded to Hold at Zacks Investment ResearchCelsion (CLSN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 11 at 7:48 PM
Zacks: Analysts Anticipate Celsion Co. (CLSN) to Announce -$0.31 Earnings Per ShareZacks: Analysts Anticipate Celsion Co. (CLSN) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - January 10 at 5:28 PM
Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by BrokeragesCelsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 10 at 8:18 AM
Celsions Phase I/II Cancer Study Initiation Gets FDA Nod - NasdaqCelsion's Phase I/II Cancer Study Initiation Gets FDA Nod - Nasdaq
www.nasdaq.com - January 5 at 4:54 PM
FDA Win Sends Celsion Corporation (CLSN) Shares Higher - Investorplace.comFDA Win Sends Celsion Corporation (CLSN) Shares Higher - Investorplace.com
investorplace.com - January 5 at 4:54 PM
FDA Win Sends Celsion Corporation (CLSN) Shares HigherFDA Win Sends Celsion Corporation (CLSN) Shares Higher
investorplace.com - January 4 at 4:14 PM
Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian CancerCelsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer
finance.yahoo.com - January 4 at 9:41 AM
Celsion shares rise 20% after FDA clears its ovarian cancer therapy for a phase 1/2 trialCelsion shares rise 20% after FDA clears its ovarian cancer therapy for a phase 1/2 trial
finance.yahoo.com - January 4 at 9:41 AM
Celsion Corporation (CLSN) Shares on the Rise; Here’s WhyCelsion Corporation (CLSN) Shares on the Rise; Here’s Why
finance.yahoo.com - January 4 at 9:41 AM
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision DrillingZacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
finance.yahoo.com - January 4 at 9:41 AM
ETFs with exposure to Celsion Corp. : January 2, 2018ETFs with exposure to Celsion Corp. : January 2, 2018
finance.yahoo.com - January 2 at 6:24 PM
Zacks: Brokerages Anticipate Celsion Co. (CLSN) Will Post Quarterly Sales of $130,000.00Zacks: Brokerages Anticipate Celsion Co. (CLSN) Will Post Quarterly Sales of $130,000.00
www.americanbankingnews.com - December 27 at 1:40 PM
 Brokerages Anticipate Celsion Co. (CLSN) to Post -$0.31 EPS Brokerages Anticipate Celsion Co. (CLSN) to Post -$0.31 EPS
www.americanbankingnews.com - December 25 at 5:08 AM
ETFs with exposure to Celsion Corp. : December 22, 2017ETFs with exposure to Celsion Corp. : December 22, 2017
finance.yahoo.com - December 22 at 8:55 PM
Celsion (CLSN) Upgraded to "Hold" by Zacks Investment ResearchCelsion (CLSN) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - December 19 at 9:02 PM
Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by AnalystsCelsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM

SEC Filings

Celsion (NASDAQ:CLSN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celsion (NASDAQ:CLSN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celsion (NASDAQ CLSN) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.